Introduction
The renin-angiotensin-aldosterone system (RAAS) is a key regulator of blood pressure and fluid and electrolyte homeostasis. Its primary components are 1) angiotensinogen, a globular glycoprotein that serves as the substrate for 2) renin, the enzyme that catalyzes the proteolytic conversion of angiotensinogen to the decapeptide angiotensin I (Ang I); 3) angiotensin-converting enzyme (ACE), a dipeptidyl carboxypeptidase that converts Ang I to the octapeptide angiotensin II (Ang II); 4) Ang II itself; 5) the Ang II receptor, responsible for transducing the cellular effects of Ang II; and 6) aldosterone, a steroid hormone under control of Ang II. Binding of the final product of this enzymatic cascade (Ang II) to its receptor mediates vasoconstriction and aldosterone and catecholamine release.Aldosterone release leads to net salt and water reabsorption through increased activity of the epithelial sodium channel. Inhibition of the RAAS is effective in the treatment of hypertension, chronic heart failure and progressive renal disease.
Historically, this hormonal system has been viewed as a systemic one, the various components of which were derived from different organs and were delivered to their site of action by the circulatory system. More recent evidence, using molecular and biochemical approaches, has shown that there are distinct, local renin-angiotensin systems with different mechanisms of regulation. Local renin-angiotensin systems have been proposed in the vasculature, brain, heart and kidney. However, evidence for the existence of all components of the system in physiologically relevant amounts remains elusive. Although the role of these putative local systems is unknown, it is interesting to speculate that they may serve as a mechanism for limiting the actions of Ang II to a specific organ system or physiological event.
In considering the genetic basis of hypertension, we will focus here on the RAAS. This is an entirely justifiable approach for several reasons. First, several monogenic forms of hypertension are due to mutation in genes involved in aldosterone synthesis or which affect the way in which aldosterone acts. Secondly, one-third of patients with hypertension have low renin, but inappropriately high aldosterone, drawing attention to perturbations in the system that may be implicated in the development of raised blood pressure.Thirdly, animal models of hypertension implicate, in several instances, changes in renin, angiotensinogen, ACE and aldosterone.Thus, the concept of candidature can be invoked to focus on a key physiological system that may be intimately involved in hypertension development (see Figure 1 ).
Renin
Renin is an aspartyl protease whose only known substrate is angiotensinogen, which it cleaves to release the decapeptide,Ang I. In the conventional concept of the RAAS as a circulating endocrine system, plasma renin is thought to release Ang I from circulating angiotensinogen (which is almost exclusively derived from the liver). Since the concentration of plasma angiotensinogen is many times higher than the Michaelis constant for the conversion to Ang I by renin, it was generally accepted that renin is the rate-limiting step in the enzyme cascade. Recently, however, some studies have cast doubts on the kinetics of the renin-angiotensinogen reaction, putting the substrate concentration much closer to the K m of the enzyme and transgenic models suggest that the availability of angiotensinogen is also ratelimiting. 1, 2 Renin synthesis and secretion are regulated by a number of factors. These include renal nerves, hormonal factors, sodium status and pressure responses and β-adrenergic agonists. The most important hormonal factor that influences renin release is Ang II. This has been shown to inhibit renin release as part of a negative feedback control mechanism. In man, renin is encoded by a single gene, located on chromosome 1q32. It contains 10 exons and nine introns, similar to other aspartyl proteases Renin, as the rate-limiting step in the RAAS, is an obvious candidate gene in hypertension and cardiovascular disease. Early studies in rats suggested that renin gene variation might contribute to the risk of hypertension. Blood pressure in rats that inherited a single spontaneously hypertensive rat (SHR) renin allele was found to be significantly greater than that in rats that inherited only the normotensive Lewis renin allele, suggesting that a structural alteration in the renin gene, or a closely linked gene, may be a pathogenetic determinant of increased blood pressure in human essential hypertensives. 3 Following this, the correlation of blood pressure and the renin restriction fragment length polymorphism (RFLP) was examined in 106 F2 rats produced from F1 rats, the offspring of a cross between SHR males and normotensive Wistar-Kyoto (WKY) females. The mean arterial blood pressure of F2 rats homozygous with the SHR allele was significantly higher than F2 rats that were heterozygous or homozygous for the WKY allele. 4 A number of RFLPs have been identified in the human renin gene, 5, 6 but the majority of studies using these markers have failed to show any association with blood pressure.
However, linkage of hypertension with the renin gene cannot be definitively ruled out, since the renin gene has not been investigated with highly informative markers in large studies. 7
Angiotensinogen
Angiotensinogen is the major substrate for renin and the ultimate precursor of Ang II. It shares some homology with alpha-antitrypsin and as such belongs to the superfamily of serine protease inhibitors (serpins). Structurally, it is a globular glycoprotein of molecular weight 55-65 kd. Ang I is liberated by renin cleavage of a leucine-valine bond in the N-terminal region of human angiotensinogen or a leucine-leucine bond in the angiotensinogens of other species.The majority of circulating angiotensinogen derives from the liver. The plasma serves as the major reservoir of this protein, but the levels are such that variations in plasma levels are a major determinant of RAAS activity.
There is a single gene for angiotensinogen on 1q42-43.The gene is composed of five exons and four introns and encompasses approximately 13 kb of genomic sequence. Transgenic strategies inducing over-expression of the angiotensinogen gene in mice suggest that this gene is associated with the regulation of blood pressure. In this model, introduction of multiple copies of the angiotensinogen gene led to a dose-dependent increase in blood pressure. 8 Thus, angiotensinogen is a strong candidate gene for hypertension. A number of polymorphic variants of this gene have been identified, and their association with hypertension investigated. One such variant of the angiotensinogen gene is the M235T polymorphism, which encodes for the substitution of a threonine for methionine at position 235. Interest in this polymorphism was stimulated by a siblingpair study from Salt Lake City and France, which suggested that the gene locus was associated with hypertension in men, particularly in severely affected sib-pairs. 9 Two variants of the gene, the M235T and the T174M, were found to be associated with hypertension in this study and the former was found to be associated with higher angiotensinogen plasma levels. Other studies have also found that the M235T variant is associated with essential hypertension in both American and Japanese populations. 10 The M235T polymorphism has also been found to be associated with coronary heart disease and, in addition, the T allele occurred at a higher frequency in women with EDITORIAL REVIEW pre-eclampsia. 11 Further support for a physiological role of the M235T polymorphism derives from the demonstration that it may be associated with variation in gene expression. A common variant in the proximal promoter of the angiotensinogen gene, characterised by the presence of adenine instead of guanine, has been identified. This appears to be in close linkage disequilibrium with the M235T polymorphism and appears to influence transcription of the gene. 12 The authors speculated that the T variant and its associated regulatory element were, in fact, the original version of the gene and had evolved in the sodiumdeprived conditions of the African subcontinent. In this scenario, hypertension, related to this polymorphism, develops upon a change in environment, such as an increase in sodium intake -a version of Neel's 'thrifty gene hypothesis'. 13 In contrast to these studies, there have also been a number of negative studies relating to the angiotensinogen gene and hypertension. When the angiotensinogen locus was studied, using a highly polymorphic dinucleotide repeat in the 3'-flanking region of the gene in 630 European affected sibling pairs,there was no evidence for linkage,either in the whole panel, or in family subsets selected for severity or early onset of hypertension. 14 In a study of 223 untreated hypertensives and matched controls from the East Anglian region of the UK, there was no association between the M235T polymorphism and blood pressure. 15 Similarly negative results were obtained in a German population. 16 Another study suggested that, while the angiotensinogen gene itself was associated with hypertension, the M235T polymorphism was not. 17 Thus, it is possible that genetic variation within the angiotensinogen gene may be implicated in the pathophysiology of hypertension, but the role of specific polymorphisms is less clear.
Angiotensin-converting enzyme
Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxypeptidase that converts Ang I to the potent vasoconstrictor Ang II and inactivates the vasodilator bradykinin. ACE has been extensively characterised and purified from several sources, including serum, lung, seminal fluid and plasma. It is also a member of the family of zinc metallopeptidases and contains a molar equivalent of zinc that functions in the hydrolytic step of the catalytic reaction.
ACE is an integral part of two enzymatic cascades, one leading to the generation of Ang II and the other to the degradation of bradykinin. The great variety of cardiovascular effects mediated by these vasoactive peptides and the efficacy of ACE inhibitors in the treatment of hypertension and heart failure emphasise the prominent role of ACE in the cardiovascular system.
The human ACE gene has been cloned and localised to chromosome 17q23 and it lies within the genomic region which is linked with hypertension in the SHRSP strain of rat. Most attention has been focused on the ACE gene since the discovery by Rigat of an insertion/deletion (I/D) polymorphism that accounts about half of the inter-individual variation in plasma ACE levels. This polymorphism is characterised by the presence or absence of a 287 base pair fragment within intron 16 of the ACE gene and is thus not part of the coding sequence. 18 Subsequent studies have confirmed a strong association with serum and cellular ACE levels, while cardiac ACE levels measured in human autopsy specimens are also related to the polymorphism. 19 The mean plasma ACE level in Caucasian DD homozygotes is about twice that found in II homozygotes, with an intermediate level in heterozygotes suggestive of co-dominant inheritance. It is suggested that the polymorphism is in strong linkage disequilibrium with a putative regulatory gene locus that controls ACE levels. 20
Intermediate phenotypes for the ACE I/D polymorphism
Although the D allele is a major determinant of serum ACE levels, it has been more difficult to identify an intermediate phenotype (i.e. a physiological effect) for the polymorphism that might account for any link with cardiovascular disease. Ueda found that venous levels of Ang II during Ang I infusion were higher in normotensive DD subjects than in II subjects and the dose required to raise the blood pressure by 20 mmHg (PD20) was significantly lower. 21 This response was enhanced in sodium-depleted subjects, suggesting that the polymorphism may be more important in conditions in which the RAAS is activated. Another study assessed the effect of the I/D genotype on the contractile properties of isolated internal mammary artery rings in vitro. 22 Contractile responses to Ang I were expressed as the percentage of the maximum response to Ang II and the difference in the areas between the Ang I and Ang II curves was taken to represent vascular Ang I to Ang II conversion (thus greater conversion would be associated with a smaller difference in area). Although the area between the curves did fall from II through ID to DD homozygotes, this was not significant. However, there did appear to be greater Ang I to Ang II conversion associated with the DD and ID genotypes taken together, compared with the II genotype. There was also a significantly lower sensitivity to the endotheliumdependent vasodilator methacholine in patients with the D allele, suggesting that stimulated release of nitric oxide (NO) was lower. By contrast, the increase in phenylephrine-stimulated contraction in the presence of the NO-synthase inhibitor L-NMMA (N-monomethyl arginine), was greater, suggesting higher basal NO release in those possessing the D allele. Another study investigated forearm vasodilation induced by acetylcholine (ACh) in hypertensive and normotensive individuals. 23 ACh induced less vasodilation in hypertensive DD homozygotes, but only when compared with ID and II subjects taken together. Though these results are initially persuasive, it is debatable whether analysis based on combining ID and DD genotypes is appropriate, given that the alleles are co-dominant.Thus, although the D allele is undoubtedly associated with higher ACE activity, evidence that this leads to substantial changes in tissue bioavailability is limited.
The ACE I/D polymorphism and the risk of ischaemic heart disease
Interest in this polymorphism was first generated by the finding of an excess risk of myocardial infarction (MI) in male DD homozygotes. Several other studies, in a variety of populations, have also suggested an association between the I/D polymorphism and coronary artery disease. 24, 25 In particular, two studies have shown an association between possession of the D allele and a parental or grandparental history of MI. 26 While these data were initially persuasive, there have also been a number of negative studies. In particular, Lindpaintner analysed the relationship between the polymorphism and ischaemic heart disease in the large, prospectively followed cohort of the Physicians Health Study and found no association between the ACE I/D polymorphism and the risk of ischaemic heart disease. 27 A subsequent meta-analysis gave a mean odds ratio for MI in DD homozygotes of 1.26, but a funnel plot of odds ratio against sample size suggested that publication bias may have confounded the result. 28 More recently, the ISIS III database was interrogated to examine the association between the D allele and the risk of MI in 4629 patients and 5934 controls. No significant association was found between the DD genotype and the risk of MI (odds ratio 1.10,95% CI 1.00-1.21). 29 In the same paper, the results of an up-dated meta-analysis of the association between MI and the D allele were reported. When the results from ISIS were combined with those from the larger hypothesis-generating trials (involving 200 or more cases), the odds ratio was 1.02 (99% CI 0.95 -1.11). The study was also able to assess the impact of the polymorphism on patient survival and found no association. The authors concluded that, while there may be an excess risk of MI (of approximately 10-15%) associated with the D allele,studies with more than 10,000 cases would be needed to provide a reliable answer.
The ACE I/D polymorphism and left ventricular hypertrophy
Following the initial suggestion of an association with the risk of MI, further studies have been performed to investigate the contribution of the I/D polymorphism to a variety of other conditions in which over expression of the RAAS may play a role. Thus, the relationship between the I/D polymorphism and left ventricular hypertrophy (LVH), hypertension and progressive renal disease has also been studied. Several studies have suggested that the D allele may associate with LVH, or other conditions that are due to abnormal cardiac remodelling. Biologically this would be a logical assumption, in view of the apparent increase in Ang II in subjects with this allele. Schunkert et al. found that the D allele was over-represented in subjects, drawn from a population of 711 women and 717 men, who were found to have LVH by electrocardiographic criteria. 30 The association was particularly strong in normotensive men, who would otherwise be considered at low risk for LVH, but the relationship was not present in women. Montgomery et al. found exercise-induced LV growth in young male army recruits was strongly associated with the ACE D allele. 31 However, although other studies have shown a link between the D allele and LV mass, there have been a number of negative studies as well. Kupari et al. used the more sensitive technique of echocardiography to investigate the role of the I/D polymorphism in determining LVH and found no association. 32 This was confirmed by Lindpaintner, using the cohort from the Framingham Study. 33 Other conditions reported to be associated with the I/D allele include ischaemic and idiopathic cardiomyopathy and hypertrophic cardiomyopathy (HCM), especially in families with HCM and a history of sudden death. 34 Twin studies are an attractive alternative to association studies, though recruitment is obviously harder. Only one twin study has been published investigating the role of the I/D polymorphism and cardiovascular structure. Busjahn et al. studied cardiac dimensions in 91 monozygotic (MZ) and 41 dizygotic (DZ) twins. 35 There was a significant relationship between both serum ACE activity and possession of the D allele and posterior cardiac wall thickness. However, study of the within-pair differences in wall thickness between MZ, concordant DZ and discordant DZ twins suggested a major contribution of other genes in determining cardiac structure.
Although there have been many studies of the role of the I/D polymorphism and cardiovascular disease, there is, as yet, no definite conclusion.There are many reasons for this. Many studies have been small and have lacked statistical power. Genetic heterogeneity may have confounded the results; the high frequency of the D allele limits its genetic informativeness and there is an inherent weakness in association studies -which are limited, for example, by the choice of an appropriate control population and by the fact that they take a "snap-shot" of a dynamic situation. Greatest doubt has been cast on the association between the D allele and MI,as discussed above.
The ACE I/D polymorphism and the regulation of blood pressure
There are a number of reasons for considering ACE as a candidate gene for hypertension. In a cross between stroke-prone spontaneously hypertensive rats (SHR/SP) and WKY rats, a major locus determining blood pressure was identified on chromosome 10 in close proximity to the ACE gene. 35, 36 This region is homologous to chromosome 17q in man, on which the ACE gene is located (see below). However, serum ACE activity does not correlate with blood pressure and there have been a number of studies that do not show any relationship between the ACE polymorphism and blood pressure. 37, 38 Some studies have suggested that the D allele of the ACE gene may contribute to the development of hypertension in specific populations, such as African-Americans. 39 40 This study used both the ACE I/D locus and a microsatellite associated with the human growth hormone (hGH) gene, which is tightly linked to ACE, as markers in a linkage analysis on 1044 sibling pairs from 484 families. Logistic and linear regression analyses were also performed to investigate the risk of hypertension associated with the ACE I/D polymorphism in the whole cohort. The odds ratio for hypertension among men who were homozygous at the D allele was 1.59 (95% CI, 1.13 to 2.23), but there was no such association in women. In the linkage analysis, a weak association was found between the I/D locus and the hGH microsatellite and diastolic, but not systolic, blood pressure in men, but not women. While such studies may suggest that the ACE locus is an important determinant of blood pressure, they do not exclude the possibility of an association with other genes in linkage disequilibrium with ACE. Additionally, Julier et al. performed a sib-pair analysis in 357 French and UK families, to investigate further the linkage between the homologous region on human chromosome 17 and blood pressure. 41 They found evidence that two closely linked markers, D17S183 and D17S934, were linked with hypertension, but these were located 18 centi-Morgans proximal to the ACE locus. Thus, while chromosome 17q may well contain an important blood-pressure determining locus, it is probably not ACE. Using a 10-cM density genomewide scan in participants from the Framingham Heart Study, Levy et al. found significant evidence of linkage of longitudinal systolic BP to chromosome 17q12-21, with a LOD score of 4.7, with odds of 50,000:1 in favour of linkage (corresponding p value of 0.0000016). 42 Many known genes and expressed sequence tags lie in or near the 16-cM QTL interval at 17q12-21. No genes that have been strongly implicated in BP variation lie in this interval; however, potential candidate genes in the interval include α-1 thyroid receptors, the neuronal homologue of the amiloride-sensitive epithelial sodium channel, the corticotropinreleasing hormone receptor 1, insulin-like growth factor-binding protein-4, hepatocyte nuclear factor 1-β and the chloride/bicarbonate exchanger AE1. It also is possible that the gene underlying the QTL locus has not yet been identified. 42 Further doubt on the role of the ACE gene in blood pressure regulation has come from studies of transgenic models. Krege et al. found that mice heterozygous for an insertional mutation that inactivates the ACE gene had a lower blood pressure than controls. 43 However, a subsequent study from the same group found that (in marked contrast to animals over-expressing the angiotensinogen gene) over-expression of the ACE gene had no effect on blood pressure, despite markedly higher serum ACE levels. 43 Thus, the weight of evidence is against any significant role of the ACE gene in determining blood pressure, or the risk of developing hypertension.
Angiotensin II receptor
Ang II acts at two principal receptors, though the existence of others has been postulated. Most of the known biological actions of Ang II are through binding to the type 1 (AT 1 )-receptor. A second major receptor subtype, the AT 2 -receptor (AT 2 ) has also been identified. Both the AT 1 -and AT 2receptors are members of the family of receptors with seven transmembrane hydrophobic domains and are G-protein coupled. They are encoded by distinct genes and have only a 32% sequence homology. Pharmacologically, they can be distinguished by their different binding affinities, AT 1receptors showing a high affinity for the Ang II antagonist losartan, and AT 2 -receptors for the compounds CGP42112A and PD 123177. 44, 45 Since Ang II acts principally on the AT 1 -receptor, it is an obvious candidate gene for cardiovascular disease. However, there is relatively little information on genetic variation in and around the receptor. One polymorphism that alters amino acid sequence has been identified at nucleotide 1166.This has been investigated in relation to cardiovascular function. The C allele of the A1166C polymorphism of the AT 1 -receptor gene has been associated with hypertension in a small population of 206 patients. 46 However, subsequent studies have been contradictory. One case-control study showed that the frequency of the C allele was increased in a group of 108 hypertensive patients with a strong family history and early onset of disease. 47 However, a further study failed to show any influence of this polymorphism on blood pressure within a group of patients without hypertension. 48, 49 The A1166C polymorphism and the risk of ischaemic heart disease The role of polymorphisms within the AT 1 -receptor in determining cardiovascular risk has also been investigated. Following the demonstration of a putative association between the ACE I/D polymorphism and MI, a similar analysis was performed for the A1166C polymorphism. 50 Although the frequency of the C allele was not increased in patients with MI, there appeared to be an interaction with the ACE DD genotype, such that the odds ratio for MI in DD homozygotes was increased in patients also carrying the C allele. This result was not replicated in a similar study from Norway, though there was a suggestion that the frequency of the C allele was increased in patients with MI who were thought to have been at low risk (low body mass index and apolipoprotein B levels). 51 Since these early studies, there have been a variety of others considering the effect of this polymorphism on cardiovascular risk and progressive renal disease but no consistent association has been found.
Several studies have investigated the effect of the A1166C polymorphism of the AT 1 -receptor on vascular structure. Benetos et al. studied the relationship between possession of the C allele and pulse wave velocity (hence arterial compliance) in normotensive and hypertensive patients. The C allele was found to be associated with higher pulse wave velocity and lower arterial compliance. 52 A further study investigated the interaction between this polymorphism and treatment of hypertension with a calcium channel blocker, nitrendipine, and the ACE inhibitor perindopril 53 Treatment with perindopril reduced pulse wave velocity (increased compliance) to a greater extent in carriers of the C allele than in AA subjects, whereas treatment with nitrendipine had the opposite effect.Thus, a genetic marker in the RAAS influenced vascular structure and appeared to determine the response to treatment. However, although this work is provocative, it has not been replicated. Castellano et al. failed to show a relationship between the A1166C polymorphism and either carotid IMT or blood pressure in a similar study. 54
Intermediate phenotypes for the A1166C polymorphism
Demonstration of an intermediate phenotype is important for a polymorphism to be considered to be physiologically significant. Such data for the A1166C polymorphism has recently been provided by Miller et al. 55 In this study, healthy, sodiumreplete men and women were chosen to form two groups characterised by the presence or absence of the C allele i.e. AA or AC/CC. Renal haemodynamic function was assessed using inulin and para-aminohippurate clearance at baseline and after administration of losartan or Ang II by infusion. Baseline glomerular filtration rate (GFR), renal plasma flow and renal blood flow were lower in the AC/CC group but there was no difference in mean arterial blood pressure (MAP). Losartan induced an increase in GFR and a fall in MAP in AC/CC, but not AA, subjects, with no effect on renal blood, or plasma, flow. Although there was a trend towards a reduction in aldosterone after losartan in AA subjects, it was significant only in AC/CC subjects. Response to Ang II infusion also varied according to genotype. Thus, Ang II induced a fall in GFR only in AC/CC subjects.These results show a clear difference in renal haemodynamics associated with this polymorphism. Since MAP was equal in the two groups, the reduced renal plasma-and blood-flow associated with the C allele reflected increased renal vascular resistance. Given the differential effects of losartan in the two groups, it is likely that this was due to increased intra-renal Ang II activity in those possessing the C allele.While initially persuasive, this was a small study and has yet to be replicated.
Further studies are required to define an intermediate phenotype of the A1166C polymorphism and, as yet, there is no convincing evidence that this marker truly associates with either cardiovascular disease or hypertension.
Aldosterone synthase
The most important regulators of aldosterone secretion are the renin-angiotensin system and serum potassium concentration.Aldosterone is synthesised from cholesterol in the zona glomerulosa of the adrenal cortex in a series of biosynthetic steps. Of these, the conversion of DOC to corticotrophin and of this to aldosterone is accomplished by the P450 enzyme aldosterone synthase. This key enzyme is encoded by the gene CYP11B2, the expression of which is regulated by Ang II and serum potassium. This gene shows a very high homology with CYP11B1,which encodes 11-β hydroxylase,which is necessary for the terminal step of cortisol synthesis.
In humans, CYP11B1 and CYP11B2 are located on chromosome 8q21-22 ( Figure 2 ). Each contains nine exons spread over approximately 7kb of DNA and approximately 40kb apart. The nucleotide sequences of these genes are 95% identical in coding regions and about 90% identical in introns. 56 It is also noteworthy that mutations in the genes encoding aldosterone synthase and 11-β hydroxylase are clearly implicated in biochemical abnormalities and raised blood pressure in the Dahl salt-sensitive hypertensive rats. There is a significant correlation of body sodium and potassium with blood pressure (BP) and aldosterone is likely to play a role in essential hypertension. 57 Aldosterone has also been shown to stimulate cardiac collagen synthesis and fibroblast proliferation via activation of local mineralocorticoid receptors in the heart (Figure 1) . In addition, aldosterone may increase cardiac load indirectly via sodium and volume retention at the distal tubulus and the collecting duct of the kidney.
There are a variety of rare monogenic human disorders involving the CYP11B2 locus in which blood pressure regulation is abnormal, drawing attention to this locus as a potential candidate in essential hypertension. Thus, mutations in CYP11B2 lead to various forms of aldosterone synthase deficiency, characterised by salt wasting and hypotension. Furthermore, unequal recombination between the two genes, leading to a duplicated hybrid CYP11B gene, causes the dominantly-inherited hypertensive disorder of glucocorticoid-remediable aldosteronism. In this disease, the hybrid gene encodes an enzyme with aldosterone synthase activity, which is expressed throughout the adrenal cortex under the control of CYP11B1 regulatory elements. Consequently, aldosterone is improperly synthesised in the zona fasciculata/reticularis of the adrenal cortex under the control of ACTH. 56 Common polymorphisms in the 5' flanking region of CYP11B2 have been documented, although none has been shown to affect expression of the gene. 56 Of these, the two most extensively studied common polymorphisms in the CYP11B2 gene are the -344C/T polymorphism and gene conversion in intron 2. The first polymorphism (-344C/T) involves a cytosine/thymidine substitution in a putative binding site for the steroidogenic transcription factor SF-1. 58 Previous studies have shown a 4-fold increase in binding of SF-1 to the -344C allele, but this does not appear to alter transcription rate.The second polymorphism is a common gene conversion in intron 2 of CYP11B2, in which most of the intron is replaced by that of CYP11B1.These two polymorphisms are in close linkage disequilibrium. Associations have been noted between -344C and other cardiovascular parameters, including increased LV diameter and mass, increased response of LV mass to dietary salt 59 and decreased baroreflex sensitivity. 60 Kupari et al. reported a strong association of the C allele with left ventricular dimensions and mass, as well as echocardiographic parameters of diastolic filling in 84 young, healthy Finnish individuals. 59 However, in a study of 2007 healthy subjects, Schunkert et al. found that echocardiographic LV wall thickness, dimensions, and mass index were not significantly associated with a specific aldosterone synthase genotype. Likewise, no association was detectable with echocardiographic measures of LV systolic or diastolic function. 61 Both LV hypertrophy and decreased baroreflex sensitivity are well-established predictors of morbidity and mortality from MI, raising the possibility that the -344C/T polymorphism may represent an independent cardiovascular risk factor.
More consistent data are available in relation to blood pressure. Several groups have reported an association between the T allele af the SF-I binding site polymorphism and hypertension in case-control studies, although a linkage study in a French sib-pair population showed negative results. 57, 62 It should, however, be recalled that association analyses are inherently more powerful at detecting genetic effects. Furthermore, we have reported that the same allele is associated with increased urinary aldosterone excretion in normal subjects. More recently, we have also reported that the T allele is increased in frequency in hypertensive subjects with a high aldosterone/renin ratio, suggesting a plausible intermediate phenotype to link the genetic variant and raised blood pressure. 63 However, not all studies of aldosterone regulation in hypertension have shown consistent data in relation to this locus, and it is clear that other influences, such as ethnicity, may need to be considered before this can be regarded as a major genetic influence on blood pressure. Nonetheless, CYP11B2 is, at present, the best example of a gene whose candidature in hypertension is supported by a clear biochemical mechanism (increased aldosterone synthesis) and a range of positive studies in different populations.
In conclusion, there is considerable evidence that genetic variation in the RAAS may influence cardiovascular structure and risk. However, the strength of the associations remain uncertain and it is likely that their importance (and particularly that of the ACE I/D polymorphism) has been overstated. The existence of numerous contradictory studies engenders scepticism, which is compounded by lack of evidence of an intermediate phenotype to link genotype and phenotype. In addition, mechanisms by which polymorphisms in non-coding regions of these genes can influence their expression have not been identified. Authors have consistently suggested that the ACE I/D and AT1R A1166C polymorphisms, for example, may be in linkage disequilibrium with regulatory elements, but these have yet to be identified or characterised at a molecular level. It is equally possible that they are also in linkage disequilibrium with other loci. Of the available evidence, the most persuasive comes from data on aldosterone synthase.This locus is implicated in animal models of raised blood pressure, rare monogenic syndromes and may also be involved in patients with essential hypertension. Finally, further work is clearly required to determine whether specific polymorphisms, or combinations of polymorphisms, will be useful in quantifying cardiovascular risk or guiding treatment. Future studies will need to consider other candidate genes, both within the RAAS and distinct from it. Other studies are already being performed which do not depend on the knowledge of a candidate gene, but
